Related Experiment Video
Updated: May 4, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
951
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies
Elias Jabbour1, Oliver G Ottmann, Michael Deininger
1ejabbour@mdanderson.org.
Haematologica
|January 16, 2014
Summary
The phosphoinositide 3-kinase (PI3K) pathway is crucial in cancer, driving growth and resistance. PI3K inhibitors show promise for treating leukemias and lymphomas, potentially improving patient outcomes when used with other therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The phosphoinositide 3-kinase (PI3K) pathway is integral to cancer cell growth, survival, and motility.
- PI3K signaling is frequently altered in various cancers, contributing to oncogenesis and therapeutic resistance.
- Understanding PI3K's role in hematologic malignancies is key for developing targeted therapies.
Purpose of the Study:
- To review the role of PI3K signaling in hematologic malignancies.
- To discuss the potential clinical utility of PI3K inhibitors in treating these cancers.
- To explore emerging data on PI3K inhibitors in combination therapies.
Main Methods:
- Review of current literature on PI3K signaling in hematologic malignancies.
- Analysis of different categories of PI3K inhibitors (dual, pan, isoform-specific).
- Evaluation of clinical data regarding PI3K inhibitors in leukemias and lymphomas.
Main Results:
- PI3K pathway alterations are common in hematologic malignancies.
- Several classes of PI3K inhibitors are under clinical investigation.
- Emerging data suggest PI3K inhibitors are promising, especially in combination therapies.
Conclusions:
- PI3K signaling is a critical target in hematologic malignancies.
- PI3K inhibitors offer potential therapeutic benefits for patients with leukemias and lymphomas.
- Further clinical evaluation of PI3K inhibitors in various treatment settings is warranted.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
5.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.1K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:20The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
01:42Phosphoinositides and PIPs
7.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K